Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPACCA: Firmonertinib vs Osimertinib or Afatinib in First-Line EGFR PACC-Mutant NSCLC
2025-522151-26-00Phase 3Authorised
- Sponsor
- ArriVent BioPharma
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by ArriVent BioPharma. Primary endpoints: Progression-free survival by BICR and Confirmed overall response rate by BICR. Planned start Dec 2025; status: authorised.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-522151-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522151-26-00.